Publicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia (34)

2024

  1. MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer

    Cell Death Discovery, Vol. 10, Núm. 1

2023

  1. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies

    Cancers, Vol. 15, Núm. 18

  2. Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

    ACS Applied Materials and Interfaces, Vol. 15, Núm. 32, pp. 38323-38334

  3. High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer

    International journal of molecular sciences, Vol. 24, Núm. 4

  4. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

    Cancers, Vol. 15, Núm. 7

2022

  1. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

  2. miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

    Cancer Communications

2021

  1. Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

    ESMO Open, Vol. 6, Núm. 1

  2. Identification of a two-microrna signature in plasma as a novel biomarker for very early diagnosis of breast cancer

    Cancers, Vol. 13, Núm. 11

2020

  1. Circulating mir-99a-5p expression in plasma: A potential biomarker for early diagnosis of breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 19, pp. 1-14

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

    Clinical Epigenetics, Vol. 11, Núm. 1

  3. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  4. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. CIP2A confirms its prognostic value in triple-negative breast cancer

    Oncogene

  2. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019

  3. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

    Scientific Reports, Vol. 7

2016

  1. C-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer

    Molecular Cancer Therapeutics, Vol. 15, Núm. 11, pp. 2780-2790

  2. DNA Methylation in Breast Cancer

    Epigenetic Biomarkers and Diagnostics (Elsevier Inc.), pp. 297-312

  3. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines

    American Journal of Cancer Research, Vol. 6, Núm. 11, pp. 2661-2678